

- Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. *Nature* 2001;411:366–374.
- Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. *Biochem Biophys Res Commun* 1963;11:39–43.
- Amé JC, Spenlehauer C, de Murcia G. The PARP superfamily. *Bioessays* 2004;26:882–893.
- Otto H, Reche PA, Bazan F, et al. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). *BMC Genomics* 2005;6:139.
- van Gent DC, Hoeijmakers JH, Kanaar R. Chromosomal stability and the DNA double-stranded break connection. *Nat Rev Genet* 2001;2:196–206.
- Shin DS, Chahwan C, Huffman JL, et al. Structure and function of the double-strand break repair machinery. *DNA Repair (Amst)* 2004;3:863–873.
- Takata M, Sasaki MS, Sonoda E, et al. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. *EMBO J* 1998;17:5497–5508.
- Rothkamm K, Krüger I, Thompson LH, et al. Pathways of DNA double-strand break repair during the mammalian cell cycle. *Mol Cell Biol* 2003;23:5706–5715.
- Stark JM, Pierce AJ, Oh J, et al. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. *Mol Cell Biol* 2004;24:9305–9316.
- Elliott B, Richardson C, Jasin M. Chromosomal translocation mechanisms at intronic alu elements in mammalian cells. *Mol Cell* 2005;17:885–894.
- Durkacz BW, Omidi O, Gray DA, et al. (ADP-ribose)<sub>n</sub> participates in DNA excision repair. *Nature* 1980;283(5747):593–596.
- Tertoli L, Graziani G. Chemosensitisation by PARP inhibitors in cancer therapy. *Pharmacol Res* 2005;52:25–33.
- Wooster R, Weber BL. Breast and ovarian cancer. *N Engl J Med* 2003;348:2339–2347.
- Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. *Oncogene* 2006;25:5864–5874.
- Tutt AN, Lord CJ, McCabe N, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. *Cold Spring Harb Symp Quant Biol* 2005;70:139–148.
- Lord CJ, Ashworth A. RAD51, BRCA2 and DNA repair: a partial resolution. *Nat Struct Mol Biol* 2007;14:461–462.
- Dobzhansky T. Genetics of natural populations. Xiii. Recombination and variability in populations of *Drosophila pseudoobscura*. *Genetics* 1946;31:269–290.
- Hartwell LH, Szankasi P, Roberts CJ, et al. Integrating genetic approaches into the discovery of anticancer drugs. *Science* 1997;278:1064–1068.
- Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. *Nat Rev Cancer* 2005;5:689–698.
- Ooi SL, Pan X, Peyser BD, et al. Global synthetic-lethality analysis and yeast functional profiling. *Trends Genet* 2006;22:56–63.
- Iorns E, Lord CJ, Turner N, et al. Utilizing RNA interference to enhance cancer drug discovery. *Nat Rev Drug Discov* 2007;6:556–568.
- Noël G, Giocanti N, Fernet M, et al. Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery. *BMC Cell Biol* 2003;4:7.
- Haber JE. DNA recombination: the replication connection. *Trends Biochem Sci* 1999;24:271–275.
- Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 2005;434:917–921.
- Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 2005;434:913–917.
- Ashworth A. A synthetic lethal therapeutic approach: PARP inhibitors for the treatment of cancers deficient in double-strand break repair. *J Clin Oncol* 2008;26:3785–3790.
- McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. *Cancer Res* 2006;66:8109–8115.
- Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. *Nat Rev Cancer* 2004;4:814–819.
- Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 2009;361:123–134.
- Fong PC, Yap TA, Boss DS, et al. Poly(ADP-ribose) polymerase (PARP) inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol* 2010;28:2512–2519.
- Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet* 2010;376:245–251.
- Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. *Lancet* 2010;376:235–244.
- Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. *J Clin Oncol* 2012;30:372–379.
- Sandhu SK, Omlin A, Hylands L et al. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. *Ann Oncol* 2013;24:1416–1418.
- Fogelman DR, Wolff RA, Kopetz S, et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. *Anticancer Res* 2011;31:1417–1420.
- Maxwell KN, Domechek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. *Nat Rev Clin Oncol* 2012;9:520–528.
- Garber K. PARP inhibitors bounce back. *Nat Rev Drug Discov* 2013;12:725–727.
- Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. *Cel* 2008;133:403–414.
- Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. *EMBO Mol Med* 2009;1:315–322.
- Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. *J Natl Cancer Inst* 2003;95:1482–1485.
- Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. *Oncogene* 2006;25:5846–5853.
- Lederemann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med* 2012;366:1382–1392.
- Lederemann JA, Harter P, Gourley C. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). *J Clin Oncol* 2013;31 (suppl); abstr 5505.
- Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol* 2011;12:852–861.
- O’Shaughnessy J, Osborne C, Pippen J, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. *N Engl J Med* 2011;3:205–214.
- Mateo J, Ong M, Tan DS, et al. Appraising iniparib, the PARP inhibitor that never was—what must we learn? *Nat Rev Clin Oncol* 2013;10:688–696.
- Lord CJ, Ashworth A. The DNA damage response and cancer therapy. *Nature* 2012;481:287–294.
- Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. *Nat Med* 2013;19:1381–1388.
- Edwards S, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. *Nature* 2008;451(7182):1111–1115.
- Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. *Proc Natl Acad Sci U S A* 2008;105:17079–17084.
- Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. *Cancer* 2003;97:2187–2195.
- Pal T, Permeth-Wey J, Kapoor R, et al. Improved survival in BRCA2 carriers with ovarian cancer. *Fam Cancer* 2007;6:113–119.
- Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. *Nature* 2008;451:1116–1120.
- Barber LJ, Sandhu S, Chen L, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. *J Pathol* 2013;229:422–429.